Linetzky, Bruno

Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m 2 : SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy

de Lemos, J. A., Linetzky, B., le Roux, C. W., Laffin, L. J., Vongpatanasin, W., Fan, L., Hemmingway, A., Ahmad, N. N., Bunck, M. C., & Stefanski, A. (2024) · Hypertension

Blood Pressure and Hypertension StudiesDiabetes Treatment and Management

Cited by 64

Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial

Horn, D. B., Linetzky, B., Davies, M. J., Laffin, L. J., Wang, H., Murphy, M. A., Zimner-Rapuch, S., Lau, E., Arad, A. D., & Lee, C. J. (2026) · JAMA Internal Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 50

Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide

Linetzky, B., Sattar, N., Verma, S., Krumholz, H. M., Xie, C. C., Hoffmann, H. T., Zimner-Rapuch, S., Torcello-Gómez, A., & Stefanski, A. (2025) · Annals of Internal Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 17

Abstract 4139912: Inflammatory biomarkers in people treated with tirzepatide living with overweight or obesity, without and with T2D: a post-hoc analysis from SURMOUNT-1 and SURMOUNT-2

Sattar, N., Verma, S., Sourij, H., Wilson, J., Stefanski, A., zhang, X., Griffin, R., Ruotolo, G., & Linetzky, B. (2024) · Circulation

Adipokines, Inflammation, and Metabolic DiseasesDiabetes Treatment and Management

Cited by 10

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide

Sattar, N., Linetzky, B., Ruotolo, G., Verma, S., Sourij, H., Wang, H., Vanderman, K., Wilson, J. M., Griffin, R. M., Stefanski, A., et al. (2026) · JACC

Adipokines, Inflammation, and Metabolic DiseasesPharmacology and Obesity Treatment

Cited by 5